Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating iparomlimab and tuvonralimab in combination with SFRT and definitive chemoradiotherapy for locoregionally advanced bulky head …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Cancer | Phase 2 | Status: NOT_YET_RECRUITING